S&P 500
$5,802.82
-0.7%
-$39.19
DJI
$41,603.07
-0.6%
-$256.02
NASDAQ
$18,737.21
-1.0%
-$188.53
Bitcoin
109,690.00
+1.4%
+1,566.35
AAPL
$195.55
-2.9%
-$5.81
AMZN
$201.33
-0.9%
-$1.77
GOOG
$169.68
-1.3%
-$2.30
META
$627.70
-1.4%
-$8.87
MSFT
$451.11
-0.8%
-$3.75
NVDA
$131.48
-1.0%
-$1.36
TSLA
$339.93
-0.3%
-$1.11

Inozyme Pharma (NASDAQ: INZY)
$3.96
(-0.1%)
-$0.00
Price as of May 23, 2025, 3:58 p.m. ET
Inozyme Pharma Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Inozyme Pharma Company Info
Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. It engages in the business of developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company was founded by Axel Bolte, Joseph P. Schlessinger, and Demetrios T. Braddock in September 2015 and is headquartered in Boston, MA.
News & Analysis
No articles found.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.